Renal Disease Market is expected to generate US$ 14291.2 million at a CAGR growth of ~6.3% by the review period of 2023 | Top Key Players Abbott (US), Amgen Inc. (US), Baxter (US), Bristol-Myers Squibb Company (US), Keryx Biopharmaceuticals, Inc. (US), Ne

Diseases of the nephrons of the kidney are termed as renal diseases or nephropathy or kidney diseases. The market for global renal disease is expected to generate US$ 14291.2 million at a CAGR growth of ~6.3% by the review period of 2023.

Large and growing unmet need, low flexibility of demand for treatment due to the serious nature of the ailment, and growing screening are the critical drivers of the market. National Health Interview Survey, 2015, estimates that 4.9 million, representing 2.0 % of adults were diagnosed with kidney disease in 2015 alone. The low flexibility of demand for treatment is reflected by the large mortality rate of 15.1 deaths per 100,000 population, which makes renal disease the 9th largest cause of deaths in the U.S. thus a large market is easily comprehendible.

Get a sample report at https://www.marketresearchfuture.com/sample_request/3167 .

Prominent Players for Global Renal disease Market:

Sanofi, Abbott, Shire Pharmaceuticals Limited, NephroGenex, Inc., Amgen Inc., Baxter, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Keryx Biopharmaceuticals, Inc., and others.

The growth is risk factors associated with kidney diseases such as alcoholism, high blood pressure, diabetes and others is the second important driver. According to the National Institute of Diabetes and Digestive and Kidney Diseases approximately half cases of kidney diseases are associated with diabetes, cardiovascular diseases and other ailments.

The high demand for sustenance treatment such as dialysis is further stimulation the market as can be seen from the data of National Institute of Diabetes and Digestive and Kidney Diseases which predict 468,000 U.S. patients are on dialysis with 661,000 Americans suffering from kidney failure. The figures for kidney transplant corresponds roughly to 193,000 patients in U.S. alone in 2015. Other drivers of the market are growing geriatric population, rising incomes and others.

Restraints

High cost of treatment especially the dialysis equipment and kidney transplant surgeries are the critical restraints on the market.

Segments of Global Renal disease Market:                                                                                                                                       

Type - acute kidney problems (pre-renal, post-renal, renal), chronic kidney diseases, and others.

Diagnosis - Blood Tests (serum creatinine, glomerular filtration rate (GFR), blood urea nitrogen (BUN), fasting blood glucose test), urine test (urinalysis, protein urine test, micro albuminuria test, creatinine clearance test), imaging test (ultrasound, CT scan), biopsy and others.

Treatment - Drugs (anti-hypertensive drugs, anti-hyperlipidemia drugs, anti-anemic drugs, anti-inflammatory drugs, diuretic and others), Dialysis (hemodialysis, peritoneal dialysis), kidney transplant (deceased-donor kidney transplant, living-donor kidney transplant, pre-emptive kidney transplant), surgery (nephrectomy and radical nephrectomy, nephron-sparing surgery (NSS), nephrolithotripsy, extracorporeal shock wave lithotripsy (ESWL), and others), diet control and others.

More inquire at https://www.marketresearchfuture.com/enquiry/3167 .

Regional Analysis of Global Renal disease Market:

North America is expected to be the largest market for global renal disease banking on high incidence rate and the huge reimbursement. The kidney disease costs Medicare program more than USD 50 billion in 2015, representing more than 20 percent of all Medicare spending. The fee for service provisions of end stage renal diseases rose from USD 30.4 billion in 2012 to USD 30.9 billion in 2013, which represents a 1.6 % increase.

The European region is anticipated to be the second largest market led by Germany, France and the U.K. Asia-Pacific (APAC) is expected to generate the fastest growth led by China, and India. Asians have 1.4 times higher risk of developing renal diseases than Caucasians. Also Diabetes is the leading cause of renal diseases. According to American Kidney Fund, Inc. report, Diabetes is the leading cause of renal diseases causes responsible for a whopping 44% of all cases of kidney failure. India has approximately 50 million diabetes patients, which is anticipated to reach 87 million patients in 2030. Thus the diabetes capital of the world is the future market for the kidney diseases.

Middle east and Africa (ME&A) market is constrained by poor per capita income, low awareness and political conditions. However the African continent also displays the largest unmet need as Africans are almost 4 times at a higher risk to develop renal diseases as compared to Caucasians.

About us

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

P: +1 646 845 9312

W: www.marketresearchfuture.com

sales@marketresearchfuture.com

This release was published on openPR.